Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parvus

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

Roche Basel Switzerland

Roche’s newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues

- PMLiVE

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

Roche Basel Switzerland

Roche pays $1bn-plus for stake in genomics specialist

Shares in Foundation Medicine Inc doubled following the announcement

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

Roche - Basel

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

- PMLiVE

Roche’s early development head Richard Scheller to retire

Will be replaced by Michael Varney from the company's Genentech business

- PMLiVE

Roche appoints business director in Spain

Promotion for Rosi Vivancos

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links